title: Hepatocellular expression of HLA-A, B, C molecules predicts primary response to interferon in patients with chronic hepatitis C.
abstract: Primary response rate to alpha-interferon (IFN) is about 50% in patients with chronic hepatitis C. Criteria for predicting a positive primary response are lacking. HLA-A,B,C molecule expression is known to be stimulated by viral infections. In 36 consecutive interferon-treated anti-HCV positive patients with an available frozen liver biopsy sample, the predictive value of liver HLA-A,B,C expression, and of histologic, clinical, and biochemical parameters was evaluated. Response to treatment was defined by normalization of transaminases, and disappearance of serum HCV-RNA within 3 months. According to these criteria, 17 patients were classified as nonresponders and 19 were classified as responders. The pattern of HLA-A,B,C hepatocellular positivity varied from normal (negative or occasional faint staining of hepatocellular membranes) to diffuse, strong "honeycomb" positivity. The highest scores of positivity were found in nonresponder patients. The discriminant capacity of HLA-A,B,C scores of positivity was compared with clinical, biochemical and histologic parameters by discriminant analysis. HLA-A,B,C expression was found to be the main discriminant parameter, in addition to alkaline phosphate (ALP) and gamma-glutamyl-transpeptidase (GGT) which added little additional information. The higher hepatocellular expression of class I MHC molecules in nonresponder cases may reflect a different viral effect on hepatocytes, which is induced by different HCV genotypes or levels of viremia. From a clinical point of view, the pretreatment HLA-A,B,C pattern of positivity represents a powerful tool in the selection of patients for interferon treatment.
authors.affiliation: Servizio di Semeiotica Medica II, Policlinico S. Orsola, Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Ballardini
authors.forename: P
authors.initials: P
authors.lastname: Groff
authors.forename: F
authors.initials: F
authors.lastname: Giostra
authors.forename: R
authors.initials: R
authors.lastname: Francesconi
authors.forename: D
authors.initials: D
authors.lastname: Zauli
authors.forename: G
authors.initials: G
authors.lastname: Bianchi
authors.forename: M
authors.initials: M
authors.lastname: Lenzi
authors.forename: F
authors.initials: F
authors.lastname: Cassani
authors.forename: F
authors.initials: F
authors.lastname: Bianchi
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D016002:Discriminant Analysis; D005260:Female; D015234:HLA-A Antigens / Q000378:metabolism*; D015235:HLA-B Antigens / Q000378:metabolism*; D015236:HLA-C Antigens / Q000378:metabolism*; D006526:Hepatitis C / Q000378:metabolism* / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D007372:Interferons